tetano
Editor, Senior Moderator
J Korean Med Sci
. 2023 Jul 10;38(27):e205.
doi: 10.3346/jkms.2023.38.e205. Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
Jinyoung Yang[SUP] #[/SUP][SUP] 1 [/SUP], Seokhwan Hyeon[SUP] #[/SUP][SUP] 2 [/SUP], Jin Yang Baek[SUP] 1 3 [/SUP], Min Seo Kang[SUP] 1 [/SUP], Keon Young Lee[SUP] 1 [/SUP], Young Ho Lee[SUP] 1 [/SUP], Kyungmin Huh[SUP] 1 [/SUP], Sun Young Cho[SUP] 1 [/SUP], Cheol-In Kang[SUP] 1 [/SUP], Doo Ryeon Chung[SUP] 1 [/SUP], Kyong Ran Peck[SUP] 1 [/SUP], Gunho Won[SUP] 2 [/SUP], Hye Won Lee[SUP] 2 [/SUP], Kwangwook Kim[SUP] 2 [/SUP], Insu Hwang[SUP] 2 [/SUP], So Yeon Lee[SUP] 2 [/SUP], Byung Chul Kim[SUP] 2 [/SUP], Yoo-Kyoung Lee[SUP] 4 [/SUP], Jae-Hoon Ko[SUP] 5 [/SUP]
Affiliations
Tixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in Korea early 2023, but its susceptibility to tixagevimab/cilgavimab is unclear. We conducted plaque reduction neutralization test (PRNT) against BN.1 in a prospective cohort (14 patients and 30 specimens). BN.1 PRNT was conducted for one- and three-months after tixagevimab/cilgavimab administration and the average PRNT ND[SUB]50[/SUB] of each point was lower than the positive cut-off value of 20 (12.9 ± 4.5 and 13.2 ± 4.2, respectively, P = 0.825). In the paired analyses, tixagevimab/cilgavimab-administered sera could not actively neutralize BN.1 (PRNT ND[SUB]50[/SUB] 11.5 ± 2.9, P = 0.001), compared with the reserved activity against BA.5 (ND[SUB]50[/SUB] 310.5 ± 180.4). Unlike virus-like particle assay, tixagevimab/cilgavimab was not active against BN.1 in neutralizing assay, and would not be effective in the present predominance of BA.2.75 sublineages.
Keywords: BN.1 Variant; COVID-19; Evusheld; Neutralizing Antibody; SARS-CoV-2.
. 2023 Jul 10;38(27):e205.
doi: 10.3346/jkms.2023.38.e205. Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
Jinyoung Yang[SUP] #[/SUP][SUP] 1 [/SUP], Seokhwan Hyeon[SUP] #[/SUP][SUP] 2 [/SUP], Jin Yang Baek[SUP] 1 3 [/SUP], Min Seo Kang[SUP] 1 [/SUP], Keon Young Lee[SUP] 1 [/SUP], Young Ho Lee[SUP] 1 [/SUP], Kyungmin Huh[SUP] 1 [/SUP], Sun Young Cho[SUP] 1 [/SUP], Cheol-In Kang[SUP] 1 [/SUP], Doo Ryeon Chung[SUP] 1 [/SUP], Kyong Ran Peck[SUP] 1 [/SUP], Gunho Won[SUP] 2 [/SUP], Hye Won Lee[SUP] 2 [/SUP], Kwangwook Kim[SUP] 2 [/SUP], Insu Hwang[SUP] 2 [/SUP], So Yeon Lee[SUP] 2 [/SUP], Byung Chul Kim[SUP] 2 [/SUP], Yoo-Kyoung Lee[SUP] 4 [/SUP], Jae-Hoon Ko[SUP] 5 [/SUP]
Affiliations
- PMID: 37431539
- DOI: 10.3346/jkms.2023.38.e205
Tixagevimab/cilgavimab is a monoclonal antibody used to prevent coronavirus disease 2019 among immunocompromised hosts and maintained neutralizing activity against early omicron variants. Omicron BN.1 became a dominant circulating strain in Korea early 2023, but its susceptibility to tixagevimab/cilgavimab is unclear. We conducted plaque reduction neutralization test (PRNT) against BN.1 in a prospective cohort (14 patients and 30 specimens). BN.1 PRNT was conducted for one- and three-months after tixagevimab/cilgavimab administration and the average PRNT ND[SUB]50[/SUB] of each point was lower than the positive cut-off value of 20 (12.9 ± 4.5 and 13.2 ± 4.2, respectively, P = 0.825). In the paired analyses, tixagevimab/cilgavimab-administered sera could not actively neutralize BN.1 (PRNT ND[SUB]50[/SUB] 11.5 ± 2.9, P = 0.001), compared with the reserved activity against BA.5 (ND[SUB]50[/SUB] 310.5 ± 180.4). Unlike virus-like particle assay, tixagevimab/cilgavimab was not active against BN.1 in neutralizing assay, and would not be effective in the present predominance of BA.2.75 sublineages.
Keywords: BN.1 Variant; COVID-19; Evusheld; Neutralizing Antibody; SARS-CoV-2.